The global Anti-erectile Dysfunction (ED) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-erectile Dysfunction (ED) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-erectile Dysfunction (ED) Drugs.
Report Scope
The Anti-erectile Dysfunction (ED) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-erectile Dysfunction (ED) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-erectile Dysfunction (ED) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Vivus, Inc.
Lilly ICOS LLC
Pfizer
Bayer
Hims
Menarini Group
Lupin
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
General Factory
CSBio
Dong-A ST
Metuchen Pharma
Seoul Pharma
Teva Pharma
S.K. Chemicals
Segment by Type
Sildenafil (Viagra)
Vardenafil (Levitra, Staxyn)
Tadalafil (Cialis)
Avanafil (Stendra)
Udenafil (Zydena)
Others
Segment by Application
Hospital
Retail Pharmacy
Clinic
Online Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-erectile Dysfunction (ED) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-erectile Dysfunction (ED) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Overview
1.1 Product Overview and Scope of Anti-erectile Dysfunction (ED) Drugs
1.2 Anti-erectile Dysfunction (ED) Drugs Segment by Type
1.2.1 Global Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Sildenafil (Viagra)
1.2.3 Vardenafil (Levitra, Staxyn)
1.2.4 Tadalafil (Cialis)
1.2.5 Avanafil (Stendra)
1.2.6 Udenafil (Zydena)
1.2.7 Others
1.3 Anti-erectile Dysfunction (ED) Drugs Segment by Application
1.3.1 Global Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Clinic
1.3.5 Online Pharmacy
1.4 Global Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Anti-erectile Dysfunction (ED) Drugs Revenue 2019-2030
1.4.2 Global Anti-erectile Dysfunction (ED) Drugs Sales 2019-2030
1.4.3 Global Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Competition by Manufacturers
2.1 Global Anti-erectile Dysfunction (ED) Drugs Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Anti-erectile Dysfunction (ED) Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Anti-erectile Dysfunction (ED) Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-erectile Dysfunction (ED) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-erectile Dysfunction (ED) Drugs, Product Type & Application
2.7 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Competitive Situation and Trends
2.7.1 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-erectile Dysfunction (ED) Drugs Players 麻豆原创 Share by Revenue
2.7.3 Global Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-erectile Dysfunction (ED) Drugs Retrospective 麻豆原创 Scenario by Region
3.1 Global Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anti-erectile Dysfunction (ED) Drugs Global Anti-erectile Dysfunction (ED) Drugs Sales by Region: 2019-2030
3.2.1 Global Anti-erectile Dysfunction (ED) Drugs Sales by Region: 2019-2024
3.2.2 Global Anti-erectile Dysfunction (ED) Drugs Sales by Region: 2025-2030
3.3 Global Anti-erectile Dysfunction (ED) Drugs Global Anti-erectile Dysfunction (ED) Drugs Revenue by Region: 2019-2030
3.3.1 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Region: 2019-2024
3.3.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Region: 2025-2030
3.4 North America Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Facts & Figures by Country
3.4.1 North America Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anti-erectile Dysfunction (ED) Drugs Sales by Country (2019-2030)
3.4.3 North America Anti-erectile Dysfunction (ED) Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Facts & Figures by Country
3.5.1 Europe Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anti-erectile Dysfunction (ED) Drugs Sales by Country (2019-2030)
3.5.3 Europe Anti-erectile Dysfunction (ED) Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anti-erectile Dysfunction (ED) Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Anti-erectile Dysfunction (ED) Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anti-erectile Dysfunction (ED) Drugs Sales by Country (2019-2030)
3.7.3 Latin America Anti-erectile Dysfunction (ED) Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anti-erectile Dysfunction (ED) Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anti-erectile Dysfunction (ED) Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-erectile Dysfunction (ED) Drugs Sales by Type (2019-2030)
4.1.1 Global Anti-erectile Dysfunction (ED) Drugs Sales by Type (2019-2024)
4.1.2 Global Anti-erectile Dysfunction (ED) Drugs Sales by Type (2025-2030)
4.1.3 Global Anti-erectile Dysfunction (ED) Drugs Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Type (2019-2030)
4.2.1 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Type (2019-2024)
4.2.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Type (2025-2030)
4.2.3 Global Anti-erectile Dysfunction (ED) Drugs Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Anti-erectile Dysfunction (ED) Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anti-erectile Dysfunction (ED) Drugs Sales by Application (2019-2030)
5.1.1 Global Anti-erectile Dysfunction (ED) Drugs Sales by Application (2019-2024)
5.1.2 Global Anti-erectile Dysfunction (ED) Drugs Sales by Application (2025-2030)
5.1.3 Global Anti-erectile Dysfunction (ED) Drugs Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Application (2019-2030)
5.2.1 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Application (2019-2024)
5.2.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Application (2025-2030)
5.2.3 Global Anti-erectile Dysfunction (ED) Drugs Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Anti-erectile Dysfunction (ED) Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Vivus, Inc.
6.1.1 Vivus, Inc. Corporation Information
6.1.2 Vivus, Inc. Description and Business Overview
6.1.3 Vivus, Inc. Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Vivus, Inc. Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.1.5 Vivus, Inc. Recent Developments/Updates
6.2 Lilly ICOS LLC
6.2.1 Lilly ICOS LLC Corporation Information
6.2.2 Lilly ICOS LLC Description and Business Overview
6.2.3 Lilly ICOS LLC Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Lilly ICOS LLC Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.2.5 Lilly ICOS LLC Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pfizer Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Corporation Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bayer Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 Hims
6.5.1 Hims Corporation Information
6.5.2 Hims Description and Business Overview
6.5.3 Hims Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Hims Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.5.5 Hims Recent Developments/Updates
6.6 Menarini Group
6.6.1 Menarini Group Corporation Information
6.6.2 Menarini Group Description and Business Overview
6.6.3 Menarini Group Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Menarini Group Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.6.5 Menarini Group Recent Developments/Updates
6.7 Lupin
6.6.1 Lupin Corporation Information
6.6.2 Lupin Description and Business Overview
6.6.3 Lupin Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Lupin Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.7.5 Lupin Recent Developments/Updates
6.8 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
6.8.1 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Corporation Information
6.8.2 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Description and Business Overview
6.8.3 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.8.5 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Recent Developments/Updates
6.9 General Factory
6.9.1 General Factory Corporation Information
6.9.2 General Factory Description and Business Overview
6.9.3 General Factory Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 General Factory Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.9.5 General Factory Recent Developments/Updates
6.10 CSBio
6.10.1 CSBio Corporation Information
6.10.2 CSBio Description and Business Overview
6.10.3 CSBio Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 CSBio Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.10.5 CSBio Recent Developments/Updates
6.11 Dong-A ST
6.11.1 Dong-A ST Corporation Information
6.11.2 Dong-A ST Anti-erectile Dysfunction (ED) Drugs Description and Business Overview
6.11.3 Dong-A ST Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Dong-A ST Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.11.5 Dong-A ST Recent Developments/Updates
6.12 Metuchen Pharma
6.12.1 Metuchen Pharma Corporation Information
6.12.2 Metuchen Pharma Anti-erectile Dysfunction (ED) Drugs Description and Business Overview
6.12.3 Metuchen Pharma Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Metuchen Pharma Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.12.5 Metuchen Pharma Recent Developments/Updates
6.13 Seoul Pharma
6.13.1 Seoul Pharma Corporation Information
6.13.2 Seoul Pharma Anti-erectile Dysfunction (ED) Drugs Description and Business Overview
6.13.3 Seoul Pharma Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Seoul Pharma Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.13.5 Seoul Pharma Recent Developments/Updates
6.14 Teva Pharma
6.14.1 Teva Pharma Corporation Information
6.14.2 Teva Pharma Anti-erectile Dysfunction (ED) Drugs Description and Business Overview
6.14.3 Teva Pharma Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Teva Pharma Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.14.5 Teva Pharma Recent Developments/Updates
6.15 S.K. Chemicals
6.15.1 S.K. Chemicals Corporation Information
6.15.2 S.K. Chemicals Anti-erectile Dysfunction (ED) Drugs Description and Business Overview
6.15.3 S.K. Chemicals Anti-erectile Dysfunction (ED) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 S.K. Chemicals Anti-erectile Dysfunction (ED) Drugs Product Portfolio
6.15.5 S.K. Chemicals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-erectile Dysfunction (ED) Drugs Industry Chain Analysis
7.2 Anti-erectile Dysfunction (ED) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-erectile Dysfunction (ED) Drugs Production Mode & Process
7.4 Anti-erectile Dysfunction (ED) Drugs Sales and 麻豆原创ing
7.4.1 Anti-erectile Dysfunction (ED) Drugs Sales Channels
7.4.2 Anti-erectile Dysfunction (ED) Drugs Distributors
7.5 Anti-erectile Dysfunction (ED) Drugs Customers
8 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Dynamics
8.1 Anti-erectile Dysfunction (ED) Drugs Industry Trends
8.2 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Drivers
8.3 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Challenges
8.4 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Vivus, Inc.
Lilly ICOS LLC
Pfizer
Bayer
Hims
Menarini Group
Lupin
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
General Factory
CSBio
Dong-A ST
Metuchen Pharma
Seoul Pharma
Teva Pharma
S.K. Chemicals
听
听
*If Applicable.